{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.63","upperLimit":"6.97","value":"5.9"},{"comment":"The upper bound of the CI could not be estimated due to insufficient number of participants with event","groupId":"OG001","lowerLimit":"4.83","upperLimit":"NA","value":"6.9"},{"comment":"95% confidence interval could not be calculated for 1 participant.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"In participants with a decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later.\n\nIn participants with no decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks.\n\nTime to PSA progression is defined as the time from the date of randomization to the first PSA progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEDIAN","populationDescription":"The ITT population for Part 1 was used for this analysis. Only 3 of 7 participants were treated in the in the control arm. Of the 3 participants treated in the control arm, only 1 participant had an event.\n\nParticipants in Part 2 did not have mCRPC, so were not assessed using PSA measurement.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout study participation. Average duration of participation, 10 months.","title":"Part 1: Time to PSA Progression Per PCWG3 Criteria","type":"SECONDARY","unitOfMeasure":"months"}